vs
Side-by-side financial comparison of CHAMPIONS ONCOLOGY, INC. (CSBR) and Outdoor Holding Co (POWW). Click either name above to swap in a different company.
CHAMPIONS ONCOLOGY, INC. is the larger business by last-quarter revenue ($15.0M vs $13.4M, roughly 1.1× Outdoor Holding Co). Outdoor Holding Co runs the higher net margin — 16.7% vs 1.8%, a 14.9% gap on every dollar of revenue. On growth, CHAMPIONS ONCOLOGY, INC. posted the faster year-over-year revenue change (11.5% vs -54.1%). Outdoor Holding Co produced more free cash flow last quarter ($5.0M vs $-2.0M).
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
Vista Outdoor Inc. was an American designer, manufacturer, and marketer that operated in two segments: shooting sports and outdoor products. It was a "house of brands" with more than 40 labels and subsidiaries.
CSBR vs POWW — Head-to-Head
Income Statement — Q2 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $13.4M |
| Net Profit | $268.0K | $2.2M |
| Gross Margin | 51.7% | 87.1% |
| Operating Margin | 1.2% | 14.7% |
| Net Margin | 1.8% | 16.7% |
| Revenue YoY | 11.5% | -54.1% |
| Net Profit YoY | -63.2% | 108.5% |
| EPS (diluted) | $0.02 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.0M | $13.4M | ||
| Q3 25 | $14.0M | $12.0M | ||
| Q2 25 | $12.4M | $11.9M | ||
| Q1 25 | $17.0M | $12.6M | ||
| Q4 24 | $13.5M | $12.5M | ||
| Q3 24 | $14.1M | $12.0M | ||
| Q2 24 | $14.0M | $12.3M | ||
| Q1 24 | $12.0M | $-50.7M |
| Q4 25 | $268.0K | $2.2M | ||
| Q3 25 | $-436.0K | $1.4M | ||
| Q2 25 | $-1.8M | $-6.5M | ||
| Q1 25 | $4.5M | $-77.5M | ||
| Q4 24 | $728.0K | $-26.1M | ||
| Q3 24 | $1.3M | $-12.4M | ||
| Q2 24 | $-109.0K | $-14.8M | ||
| Q1 24 | $-2.5M | $-5.2M |
| Q4 25 | 51.7% | 87.1% | ||
| Q3 25 | 42.9% | 87.1% | ||
| Q2 25 | 41.1% | 87.2% | ||
| Q1 25 | 61.2% | 87.5% | ||
| Q4 24 | 44.9% | 87.4% | ||
| Q3 24 | 49.7% | 86.9% | ||
| Q2 24 | 48.2% | 85.8% | ||
| Q1 24 | 34.7% | — |
| Q4 25 | 1.2% | 14.7% | ||
| Q3 25 | -3.8% | 5.9% | ||
| Q2 25 | -16.2% | -50.7% | ||
| Q1 25 | 26.4% | -213.6% | ||
| Q4 24 | 5.4% | -163.8% | ||
| Q3 24 | 9.5% | -50.3% | ||
| Q2 24 | -1.9% | -50.8% | ||
| Q1 24 | -21.4% | — |
| Q4 25 | 1.8% | 16.7% | ||
| Q3 25 | -3.1% | 11.7% | ||
| Q2 25 | -14.9% | -54.5% | ||
| Q1 25 | 26.4% | -614.5% | ||
| Q4 24 | 5.4% | -208.7% | ||
| Q3 24 | 9.3% | -103.7% | ||
| Q2 24 | -0.8% | -120.2% | ||
| Q1 24 | -21.1% | 10.3% |
| Q4 25 | $0.02 | $0.01 | ||
| Q3 25 | $-0.03 | $0.01 | ||
| Q2 25 | $-0.12 | $-0.06 | ||
| Q1 25 | $0.31 | $-0.67 | ||
| Q4 24 | $0.05 | $-0.23 | ||
| Q3 24 | $0.09 | $-0.11 | ||
| Q2 24 | $-0.01 | $-0.13 | ||
| Q1 24 | $-0.19 | $-0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $69.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.2M | $237.3M |
| Total Assets | $30.2M | $271.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $69.9M | ||
| Q3 25 | $10.3M | $65.7M | ||
| Q2 25 | $9.8M | $63.4M | ||
| Q1 25 | $3.2M | $30.2M | ||
| Q4 24 | $2.8M | $31.9M | ||
| Q3 24 | $2.9M | $33.5M | ||
| Q2 24 | $2.6M | $50.8M | ||
| Q1 24 | $4.5M | $55.6M |
| Q4 25 | $4.2M | $237.3M | ||
| Q3 25 | $3.5M | $235.4M | ||
| Q2 25 | $3.8M | $222.5M | ||
| Q1 25 | $5.5M | $222.0M | ||
| Q4 24 | $681.0K | $299.6M | ||
| Q3 24 | $-332.0K | $325.6M | ||
| Q2 24 | $-1.9M | $342.5M | ||
| Q1 24 | $-2.1M | $358.0M |
| Q4 25 | $30.2M | $271.7M | ||
| Q3 25 | $30.5M | $270.3M | ||
| Q2 25 | $32.3M | $269.5M | ||
| Q1 25 | $30.6M | $297.3M | ||
| Q4 24 | $25.2M | $355.4M | ||
| Q3 24 | $24.9M | $368.9M | ||
| Q2 24 | $26.1M | $398.6M | ||
| Q1 24 | $26.8M | $403.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $5.7M |
| Free Cash FlowOCF − Capex | $-2.0M | $5.0M |
| FCF MarginFCF / Revenue | -13.1% | 37.6% |
| Capex IntensityCapex / Revenue | 1.6% | 4.8% |
| Cash ConversionOCF / Net Profit | -6.47× | 2.55× |
| TTM Free Cash FlowTrailing 4 quarters | $5.6M | $-2.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $5.7M | ||
| Q3 25 | $600.0K | $3.2M | ||
| Q2 25 | $6.9M | $-6.7M | ||
| Q1 25 | $490.0K | $-1.5M | ||
| Q4 24 | $-283.0K | $1.3M | ||
| Q3 24 | $311.0K | $-9.3M | ||
| Q2 24 | $-1.8M | $-547.5K | ||
| Q1 24 | $-919.0K | $4.3M |
| Q4 25 | $-2.0M | $5.0M | ||
| Q3 25 | $554.0K | $2.5M | ||
| Q2 25 | $6.6M | $-7.6M | ||
| Q1 25 | $448.0K | $-2.3M | ||
| Q4 24 | $-377.0K | $720.3K | ||
| Q3 24 | — | $-10.6M | ||
| Q2 24 | $-1.8M | $-1.3M | ||
| Q1 24 | $-1.0M | $1.4M |
| Q4 25 | -13.1% | 37.6% | ||
| Q3 25 | 4.0% | 21.0% | ||
| Q2 25 | 53.5% | -63.8% | ||
| Q1 25 | 2.6% | -18.6% | ||
| Q4 24 | -2.8% | 5.8% | ||
| Q3 24 | — | -88.3% | ||
| Q2 24 | -13.0% | -11.0% | ||
| Q1 24 | -8.4% | -2.8% |
| Q4 25 | 1.6% | 4.8% | ||
| Q3 25 | 0.3% | 5.8% | ||
| Q2 25 | 2.0% | 7.5% | ||
| Q1 25 | 0.2% | 6.5% | ||
| Q4 24 | 0.7% | 4.4% | ||
| Q3 24 | 0.0% | 10.4% | ||
| Q2 24 | 0.0% | 6.5% | ||
| Q1 24 | 0.8% | -5.7% |
| Q4 25 | -6.47× | 2.55× | ||
| Q3 25 | — | 2.29× | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.11× | — | ||
| Q4 24 | -0.39× | — | ||
| Q3 24 | 0.24× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
POWW
Segment breakdown not available.
